Analyst Maintains Hold on Aldeyra Amid FDA Uncertainty Over Reproxalap’s Regulatory Path
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Matthew Caufield maintains a Hold rating on Aldeyra Therapeutics with a $2.00 price target, citing regulatory uncertainty surrounding Reproxalap's FDA approval path. The FDA's Complete Response Letter noted insufficient evidence and inconsistent efficacy signals. While Aldeyra is engaging the FDA to clarify resubmission feasibility, Caufield advises waiting for clearer guidance on development timelines and costs before reassessing the risk-reward profile.
Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on Aldeyra Therapeutics. The associated price target is $2.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Matthew Caufield has given his Hold rating due to a combination of factors tied primarily to regulatory uncertainty around Reproxalap, Aldeyra’s lead RASP modulator for dry eye disease. The FDA’s Complete Response Letter highlighted a lack of persuasive, well-controlled evidence and pointed to inconsistent efficacy signals across trials, leading Caufield to wait for clearer guidance on whether and how the NDA can be successfully resubmitted.
At the same time, Caufield recognizes that Aldeyra is actively engaging the FDA through additional meetings, which could clarify the feasibility, cost, and timing of any new trials or a potential dispute resolution path. Because these outcomes could materially affect both development timelines and spending, but remain unresolved in the near term, he views a Neutral stance as appropriate until there is better visibility into the regulatory path and overall risk‑reward profile for Reproxalap and the broader platform.